

Rev03
 Update: Aug,08,2025

DATASHEET


CLEC4M/CD299, Human

Cat. No.: Z05178


Product Introduction

Species	Human
Protein Construction	CLEC4M/CD299 (Gln71-Glu399) Accession # Q9H2X3-1
Purity	> 95% as determined by BisTris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per µg by the LAL method.
Expression System	HEK293
Theoretical Molecular Weight	37.72 kDa
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result.
Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4).
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples



CLEC4M/CD299, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.



The purity of CLEC4M/CD299, Human is greater than 95% as determined by SEC-HPLC.

Background

Target Background : CLEC4M, also known as DC-SIGNR, L-SIGN or CD209L, is a Ca²⁺-dependent C-type lectin. CLEC4M and its homologue DC-SIGN are encoded by the closely related lectin gene cluster on chromosome 19p13.3. Higher expression of CLEC4M is associated with poor clinical prognosis in lung cancer patients and enhances the resistance of NSCLC cells to cisplatin. Inhibition of CLEC4M expression significantly increased cisplatin sensitivity, suggesting potential clinical significance for targeting CLEC4M in overcoming cisplatin resistance.

Synonyms : CLEC4M; CD299; DC-SIGNR; DC-SIGN2; L-SIGN; CD209L; CD209L1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28 Yongxi Road, Jiangning District, Nanjing, Jiangsu, China